Tag Archive for ‘MRK’

GTx Inc. (GTXI) engages in the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care and other serious medical conditions. The Company’s newest product candidate is Capesaris (GTx-758), which is being developed for first line treatment of advanced prostate cancer. GTx-758 has - Continue Reading »

Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, it is currently concentrating on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2009, ACHN focused - Continue Reading »

Cyclacel Pharmaceuticals (CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. Sapacitabine (CYC682), a cell - Continue Reading »

GTx Inc. (GTXI), a biopharmaceutical company, engages in the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care and other serious medical conditions. The Company’s newest product candidate is Capesaris (GTx-758), which is a selective estrogen receptor alpha agonist being developed for - Continue Reading »

Amgen Inc. (Nasdaq: AMGN) shares appreciated 8.7% over the last two months as the company reported significant progress with the advancement of its drug candidate Xgeva (denosumab) in patients with prostate cancer. Xgeva was approved by the U.S. Food and Drug Administration (FDA) for the prevention of skeletal-related events in patients with bone metastases from solid tumors, and succeeded to - Continue Reading »